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Abstract  
 Introduction: Hyperglycemia and insulin resistance are common in 
critically ill patients, even if they have not previously had diabetes, and the 
risk of mortality or significant morbidity is high among those who are treated 
in the intensive care unit (ICU) for more than 5 days.  
Study objectives: To assess the effect of glucose management protocol on 
mortality and morbidity in a heterogeneous population of critically ill adult 
patients. 
Methods and materials:  
Study design: A randomized controlled trial. 
Study setting: Intensive care unit (ICU) for adult patients at King Hussein 
Medical Center, the Royal Medical Services. 
Study sample: A total of 50 patients were included in this study and assigned 
randomly into two groups, control group (N=25), and intervention group 
(N=25). 
Study protocol: The intervention group subjects were to undergo a glucose 
control protocol with insulin infusion titrated to maintain blood glucose level 
in a target range of 120-160 mg/dL; except septic patients, in whom the 
target was higher, 160- 180 mg/dL. Patients in the second group (control 
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group) were treated by a conventional approach with reduction of blood 
glucose level only if the level was markedly elevated (>200 mg/dL) to 
maintain blood glucose level in a target range of 180-200 mg/dL 
Study findings: Although the difference in mortality between the two 
treatment groups was not significant at 28 days (p=0.370) and at 60 days 
(p=0.555), but it was to be considered for further improvements. No 
significant increase in hypoglycemia episodes was reported in our blood 
glucose level target. There was no significant difference in the development 
of new organ failure, new renal insufficiency, number of patients undergoing 
transfusion of packed red blood cells, use of antibiotics for more than 10 
days, length of stay in the ICU and length of stay in the hospital. It was 
noticed that the rates of positive blood cultures were lower in the 
interventional group (8%) than in the control group (32), (p=0.068).  
Conclusion: The glucose management protocol resulted in significantly 
improved glycemic control and was not associated with increased rate of 
death or hypoglycemia. 
 
Keywords: Intensive care unit (ICU), hypoglycemia, intervention, control, 
randomized controlled trial 
 
Introduction 
 Patients in the intensive care unit (ICU) are predisposed to elevated 
blood glucose levels because of common clinical interventions, such as the 
use of corticosteroids, vasopressors, glucose-containing intravenous fluids 
used for drug or fluid administration, enteral or parenteral nutrition, and 
dialysis (Krinsley, 2005). 
 
Hyperglycemia adverse clinical outcomes 
 Extensive observational data have shown a consistent, almost linear 
relationship between high blood glucose levels in hospitalized patients and 
adverse clinical outcomes, even in patients without established diabetes 
(Krinsley et al., 2003). 
 Hyperglycemia has been identified as an independent risk factor for 
adverse outcome in numerous clinical settings at admission or throughout 
hospitalization. It predisposes patients to many of the typical ICU 
complications such as severe infections, sepsis, excessive inflammation, 
critical illness polyneuropathy, ICU prolonged intensive care dependence, 
prolonged need of mechanical ventilation multiple organ failure and 
excessive mortality (Vanhorebeek et al., 2007). 
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Neurology 
    Poor glycemic control, though even mildly elevated glucose levels, is 
associated with increased morbidity and mortality in critically ill brain injury 
and trauma patients; this is more pronounced in nondiabetic patients (Gale et 
al., 2007). Hyperglycemia has been reported to augment ischemic brain 
injury and worsen outcomes in many animal and human studies. One study 
evaluated 267 non-diabetic patients with non-penetrating head injuries. 
Among patients with more severe head injury, BG levels >200 mg/dL were 
associated with worse outcomes (Rovlias and Kotsou, 2000). Apart from the 
predictive value of hyperglycemia for mortality of patients with severe brain 
injury, a significant relationship was found between high blood glucose 
levels and worse neurologic status, impaired pupil reactivity, intracranial 
hypertension, and longer hospital length of stay (Bochicchio et al., 2005; 
Laird et al., 2004). 
 Similarly, hyperglycemia predicted a higher risk of death after stroke 
and a poor functional recovery in those patients who survived. Elevated brain 
glucose concentrations resulting from hyperglycemia, in conjunction with an 
ischemia-induced shift to anaerobic glycolysis, led to more severe elevations 
of brain lactic acid concentrations and more profound acidosis (Gale et al., 
2007). 
    In patients with acute ischemic stroke, negative neurologic outcomes 
associated with hyperglycemia include the evolution of hypoperfused tissue, 
greater infarct size, worse functional outcome, longer hospital stays, and 
higher hospital charges (Bruno et al., 2002). Hyperglycemia is also 
independently associated with increased mortality at 30 days, one year, and 6 
years after stroke. And when hyperglycemia is present before an ischemic or 
anoxic event, neurologic damage is worse (Parsons et al., 2002).  
 
Infections 
 Increasing evidence suggests that hyperglycemia impedes normal 
physiologic responses to infection and is statistically related to distinct 
changes of humoral and cellular immune functions (Wasmuth et al., 2004). 
High glucose levels negatively affect polymorphonuclear neutrophil function 
and intracellular bactericidal opsonic activity and causes apoptosis in 
proximal tubular epithelial cells (Allen et al., 2003). 
 
Postoperative infections 
 In vitro and in vivo studies report substantial impairment in immune 
function and wound healing associated with hyperglycemia (Weekers et al., 
2003). Mechanisms include complement inactivation, irregularities in 
granulocyte adherence, impaired phagocytosis, delayed chemotaxis and 
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oxidative burst, and decreased bactericidal activity. Collagen deposition is 
impaired, possibly due to decreased fibroblast proliferation. 
 The degree of leukocyte abnormalities varies directly with BG 
concentrations; impaired phagocytic function occurs with BG levels as low 
as 200 mg/dL. Nonenzymatic glycosylation of immunoglobulins - which 
causes their inactivation – also contributes to the risk of infection (Lewis et 
al., 2004). 
 A prospective cohort study assessed the correlation between 
preoperative glucose control and the subsequent risk of infectious 
complications in 411 diabetic patients who were undergoing coronary artery 
surgery. After adjusting for confounding variables, patients with mean BG 
concentrations more than 200 mg/dL following the surgery had higher rates 
of leg and chest wound infections, pneumonia, and urinary tract infections 
and mortality rates (Hill-Golden et al., 1999). 
 
Septic patients 
 The available literature suggests a causal link between hyperglycemia 
and adverse outcome in sepsis. In addition, a strong link has been described 
between increased blood glucose levels and the risk of critical illness 
polyneuropathy in sepsis and the systemic inflammatory response syndrome. 
Most deaths in the ICU occurring beyond the first few days of critical illness 
are attributable to non-resolving failure of multiple organ systems, either due 
to or coinciding with sepsis (Vanhorebeek et al., 2007). 
 
Mortality 
 Kosiborod et al (2005) found a relation between high admission 
glucose and increased mortality in elderly patients hospitalized with acute 
myocardial infarction (Kosiborod et al., 2005). A retrospective study was 
conducted on all injured patients admitted to the surgical ICU for more than 
48 hours. Non-survivors had higher average glucose than survivors (p<0.03). 
In ICU the mortality rate for newly hyperglycemic patients approached one 
in three (Umpierrez et al., 2002). A retrospective analysis of a heterogeneous 
population of critically ill patients revealed that even a modest degree of 
hyperglycemia was associated with increased hospital mortality (Krinsley et 
al., 2003). 
 
Controlling hyperglycemia in ICU patients 
 Although extensive research efforts during the last decade focused on 
strategies to prevent or reverse the potentially lethal multiple organ failure, 
only few of them revealed positive results. One of these strategies is blood 
glucose control with insulin (Berghe., 2004). Another way for controlling 
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hyperglycemia is by controlling the exogenous nutritional inputs (Chase et 
al., 2006). 
 
Mechanisms of blood glucose control with insulin therapy in the ICU 
 Several mechanisms are involved and interrelated in explaining the 
clinical benefits of normoglycemic control; including metabolic and non-
metabolic insulin effects, anti-inflammatory effects, prevention of glucose 
toxicity, and other direct insulin actions on several cell and organ systems. 
The relative contribution of those different mechanisms, however, is 
presently unknown (Derde et al., 2009). 
 
Lowering blood glucose levels 
 Critically ill patients suffer from both hepatic and skeletal muscle 
insulin resistance. The increased metabolic insulin signal was observed in 
postmortem skeletal muscle, but not in liver biopsies of insulin-treated 
patients. This suggests that in critically ill patients exogenous insulin does 
not affect hepatic insulin resistance and lowers blood glucose levels mainly 
through stimulation of skeletal muscle glucose uptake (Langouche et al., 
2007). Insulin therapy also attenuated the cortisol (counterregulatory 
hormone) response to critical illness, without involvement of altered cortisol-
binding activity, also suppress indirectly the synthesis and production of 
TNF and IL-2 which play a role in increased gluconeogenesis (Vanhorebeek 
et al., 2006). 
 
Study objectives 
 The main objective of the current study is to evaluate the impact of 
the blood glucose level control on the morbidity and mortality of intensive 
care unit patients. 
 
Materials and Methods  
Study design 
 A randomized, controlled trial of blood glucose management which 
involved adult medical and surgical ICU patients, who received treatment in 
the ICU for 3 or more consecutive days, at King Hussein Medical Center, 
and the Royal Medical Services. 
 
Study population 
 Adults, who were expected to require treatment in the medical and 
surgical ICU for 3 or more consecutive days, and within 24 hours after 
admission to an intensive care unit, were eligible for the study. 
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Inclusion criteria 
 Patients were eligible to participate in this study if they satisfied the 
following criteria: 
 • Patients, who were expected to require treatment in the ICU for 3 or 
more consecutive days after admission, the decision was made by the 
treating ICU specialist. 
 • Patients who had an arterial line or central line in situ or the 
placement of the lines was imminent as part of routine ICU management. 
 • Need for insulin therapy. 
 • Informed consent was approved by the patient or his/her legal 
surrogate. 
 
Exclusion criteria 
 Patients were not included if:  
 • Age is less than 18 years. 
 • Imminent death (cardiac standstill or brain death anticipated in less 
than 24 hours and the treating clinicians were not committed to full 
supportive care. 
 • Patients who were admitted to the ICU for treatment of diabetic 
ketoacidosis or for hyperosmolar state. 
 • Patients who were expected to be eating before the end of the day 
following the day of admission to the ICU. 
 • Patients who had previously suffered hypoglycemia without a 
documented full neurological recovery. 
 • Patients who were considered at abnormally high risk of suffering 
hypoglycemia (e.g.  known insulin secreting tumor or history of unexplained 
or recurrent hypoglycemia or fulminant hepatic failure). 
 • Patients who had previously been enrolled in the study. 
 • Patients who cannot provide prior informed consent and there is 
documented evidence that the patient has no legal surrogate. 
 • Patients who had been in the study ICU for more than 24 hours 
during this admission. 
 • Patients who were transferred from other hospitals (another ICU) 
and who had been in the ICU for more than 24 hours. 
 
Sample size 
 A sample was randomly selected, daily odd or even hidden numbered 
papers were picked up randomly to include eligible patients for the study, 
odd numbers were chosen for the interventions and even ones were chosen 
for the controls. Patients sample size was 50 patients. 
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Statistical Analysis 
 SAS, version 9.1, was used for statistical analysis. Clinical data were 
expressed as mean, median and as percentages. P values less than 0.05 were 
considered significant. For univariate analysis of end points Chi-square test 
or Fisher's exact test. Continuous variables were compared with the use of 
unpaired t-test, or Wilcoxon rank-sum test. 
 
Results  
Outcomes and adverse events. 
 Twenty eight days after randomization, (28%) of patients died in the 
intervention group, as compared to (42%) in the control group (Table 5). The 
difference in mortality between the two treatment groups was not significant 
after adjustment for the predefined baseline risk factors (p= 0.370). 
 Sixty days after randomization, (32%) of patients died in the 
intervention group compared to (40%) in the control group. The difference in 
mortality between the two treatment groups was not significant (p= 0.555). 
Place of death was mainly in the ICU. There was no significant difference 
between the two groups in the average median of length of stay in the ICU 
(p= 0.596) or stay in the hospital (p= 0.380). 
 The numbers of patients in whom new single or multiple organ 
failures developed were similar between the intervention and the control 
groups (p=0.142). 
 There were no significant differences between the two groups in the 
percentage of mechanical ventilation (p=0.135), number of days on 
mechanical ventilation (p=0.945) and percentage of patients who needed 
renal-replacement therapy (p= 0.139). 
 There were no significant differences between the two groups in the 
percentage of patients who received blood transfusion (p= 0.136), in the 
mean number of units of blood transfused (p=0.576), or in the percentage of 
patients using antibiotics for more than 10 days (p=0.141). The rate of 
positive blood cultures was lower in the intervention group than in the 
control group (8% and 32% respectively, p=0.068). 
 Severe hypoglycemia (defined as a blood glucose level 45 mg/dL) 
was not observed in patients of either groups, and study treatment was not 
discontinued prematurely because no serious adverse events were noticed. 
 The recorded number of episodes of hypoglycemia was 2 in the 
intervention group, as compared to zero episodes in the control group 
(p=0.148); as confirmed by a laboratory measurement. The time spent in the 
hypoglycemic range was negligible (less than 2 hours), and resulted in rescue 
dextrose administration. 
 Secondary subgroup analysis for the primary outcome were based on 
an unadjusted test of interaction in a logistic regression model , with the 
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strata used for randomization (type of admission) as covariates, as well as 
age, gender, diabetes, location before ICU admission, and use of mechanical 
ventilation at baseline, septic shock and trauma. 
 A significant association was observed with the type of admission for 
death at 28 days with higher mortality rate for medical ICU than surgical 
ICU (p=0.015), and at 60 days it was still significant (p=0.032). 
 No association was observed between diabetic and non -diabetic 
patients for death. The time from randomization to death in the two treatment 
groups was not significantly different compared with the use of the log-rank 
test, and the results are presented as Kaplan–Meier curves and are shown in 
figure 1. 
Table 1: Outcomes and Adverse Events associated with study protocol  
Outcome measure  
 
Intervention group Control group P-value 
Death, (%) 
At day 60 
At day 28 
32 % 
28% 
40% 
40% 
0.555 
0.370 
Hypoglycemia, (%)  8% 0% 0.148 
Days in the ICU, median 
(minimum-maximum)  
5 (3-33) 6 (3-34) 
 
0.596 
Days in the hospital, median 
(minimum-maximum)  
3 (0-22) 3 (0-14) 0.380 
Mechanical ventilation, (%)  92% 84% 0.135 
Days on mechanical ventilation, 
median (minimum-maximum)  
4 (2-20) 5 (2-25) 0.945 
Renal replacement therapy, (%)  8% 12% 0. 139 
No. of new organ failures, (%) 
0 
1 
2 
3 and more 
 
64% 
24% 
8% 
4% 
 
56% 
20% 
24% 
0% 
0.142 
Blood culture positive for pathogenic 
organisms, (%)  
8% 36% 0.068 
Use of antibiotics for more than 10 
days, (%)  
40% 44% 0.141 
Transfusion of packed red cells, (%)  68% 84% 0.136 
No. of units of packed cells 
transfused, 
mean ±SD  
2.56 ± 1.95 2.24 ± 2.067 0.576 
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Figure 1: Kaplan–Meier curves of probability of survival at 28 days and 60 days 
 
Discussion 
 In this randomized controlled trial involving adults in the mixed ICU, 
we found that a new target of blood glucose control that was used in the 
intervention group, as compared with a conventional glucose control in the 
control group, did not increase the absolute risk of death at 28 days and at 60 
days. 
 The difference in mortality remained not significant after adjustment 
for potential confounders at 28 days (p=0.370), and at 60 days (p=0.555), 
between two groups in our study. This finding agrees with the result of a 
meta-analysis stating that the different targets ofintensive insulin therapy 
(glucose level [ 6.1 mmol/L versus [ 8.3 mmol/L) did not influence either 
mortality (Fahey et al., 2009). 
 It was noticed by secondary subgroup analysis for the primary 
outcome that the percentage of death was significantly higher in medical 
ICU patients than surgical ICU patients (p= 0.015), indicating that surgical 
patients may benefit more from insulin treatment. As found in previous 
studies (Van den Berghe et al., 2001, He et al., 2007) and a meta-analysis 
(Donald et al., 2009). There was no significant difference in other secondary 
outcomes between the two groups; in the median length of stay in the ICU or 
in the hospital, the need for mechanical ventilation and renal-replacement 
therapy, the need for blood transfusion and new organ failures that developed 
during admission. 
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 In our study the rate of positive blood cultures was lower in the 
intervention group than that in the control group; (8% and 32% respectively) 
(p=0.068), which reflects reduction in the risk of septicemia. In this 
randomized controlled trial involving adults in the mixed ICU we found that 
a new target of blood glucose control that was used in the intervention group, 
as compared with a conventional glucose control in the control group, did 
not increase the absolute risk of death at 28 days and at 60 days. 
 The difference in mortality remained not significant after adjustment 
for potential confounders at 28 days (p=0.370), and at 60 days (p=0.555), 
between two groups in our study. This finding agrees with the result of a 
meta-analysis stating that the different targets of intensive insulin therapy 
(glucose level [ 6.1 mmol/L versus [ 8.3 mmol/L) did not influence either 
mortality (Fahey et al., 2009). 
 It was noticed by secondary subgroup analysis for the primary 
outcome that the percentage of death was significantly higher in medical 
ICU patients than surgical ICU patients (p= 0.015), indicating that surgical 
patients may benefit more from insulin treatment. As found in previous 
studies (Van den Berghe et al., 2001, He et al., 2007) and a meta-analysis 
(Donald et al., 2009). 
 There was no significant difference in other secondary outcomes 
between the two groups; in the median length of stay in the ICU or in the 
hospital, the need for mechanical ventilation and renal-replacement therapy, 
the need for blood transfusion and new organ failures that developed during 
admission. 
 In our study the rate of positive blood cultures was lower in the 
intervention group than that in the control group; (8% and 32% respectively) 
(p=0.068), which reflects reduction in the risk of septicemia. This finding 
was reported previously by other studies (Van den Berghe, et al., 2001; 
Grey, et al., 2004). 
 There was no significant difference in the percentage of patient to 
whom antibiotics was used for more than 10 days between the two groups in 
our study; due to the fact that some patients were inappropriately given 
antibiotics until the day of discharge in an attempt to prevent infections while 
they were hospitalized may have led to the use of antibiotics for longer than 
the recommended period so we could not detect difference. 
 The basic clinical characteristics of all patients enrolled in our study 
showed that the mean HbA1C was less than 6.5% indicating that 
hyperglycemia was not sustained and that both diabetic and non-diabetic 
patient in the ICU revealed stress induced hyperglycemia. 
 On the basis of our data, we speculate that a target blood glucose 
level of less than 160 mg/dL may be adequate. This more relaxed target for 
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glucose control with a range of 40 mg/dL will be likely associated with less 
risk of inadvertent hypoglycemia than other suggested targets. 
 Evidence exists that intensive insulin therapy prevents complications 
such as severe nosocomial infections, acute renal failure, liver dysfunction, 
critical illness polyneuropathy, muscle weakness, and anemia, and, thus, 
reduces the time that patients are dependent on intensive care. The use of 
insulin therapy to maintain normoglycemia for at least a few days improves 
survival and reduces morbidity (Vanhorebeek et al., 2006). 
 
Conclusion 
 Hyperglycemia develops commonly in the critically ill and impacts 
outcome in patients with diabetes but, even more so, in patients with stress-
induced hyperglycemia. The data of the present study showed that a blood 
glucose target of less than 160 mg per deciliter in general, and target of less 
than 180 for septic patients, did not significantly increase mortality more 
than a target of less than 200 mg /per deciliter among critically ill adult 
patients. 
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